Evidence map›Paper›PMID 40312753›Full record

ArticleBreast cancer research : BCR2025

Development and validation of a risk prediction model for premenopausal breast cancer in 19 cohorts.

Kristen D Brantley, Michael E Jones, Rulla M Tamimi, Bernard A Rosner, Peter Kraft, Hazel B Nichols, Katie M O'Brien, Hans-Olov Adami, Amaia Aizpurua, Amy Berrington de González and 37 more

Abstract readValidation Study
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

47 authors.

Kristen D BrantleyDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA. kbrantley@g.harvard.edu.
Michael E JonesDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
Rulla M TamimiDepartment of Population Health Sciences, Weill Cornell Medicine, New York, NY, USA.
Bernard A RosnerDepartment of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Peter KraftDivision of Cancer Epidemiology and Genetics, Transdivisional Research Program, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Hazel B NicholsUniversity of North Carolina, Gillings School of Global Public Health, Chapel Hill, NC, USA.
Katie M O'BrienEpidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA.
Hans-Olov AdamiDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Amaia AizpuruaMinistry of Health of the Basque Government, Sub Directorate for Public Health and Addictions of Gipuzkoa, San Sebastian, Spain.
Amy Berrington de GonzálezClinical Cancer Epidemiology, Institute of Cancer Research, Sutton, London, UK.
William J BlotDepartment of Medicine, Division of Epidemiology, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, TN, USA.
Tonje BraatenDepartment of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
Yu ChenDepartment of Population Health, Division of Epidemiology, NYU Grossman School of Medicine, New York, NY, USA.
Jessica Clague DeHartSchool of Community and Global Health, Claremont Graduate University, Claremont, CA, US.
Laure DossusNutrition and Metabolism Branch, International Agency for Research On Cancer, Lyon, France.
Sjoerd EliasJulius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
Renée T FortnerDivision of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
Montserrat Garcia-ClosasCancer Epidemiology and Prevention Unit, Institute of Cancer Research, Sutton, London, UK.
Inger T GramDepartment of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
Niclas HåkanssonInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Susan E HankinsonDepartment of Biostatistics and Epidemiology, School of Public Health and Health Sciences, University of Massachusetts, Amherst, MA, USA.
Cari M KitaharaDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD, USA.
Woon-Puay KohHealthy Longevity Translational Research Programme, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore.
Martha S LinetDivision of Cancer Epidemiology and Genetics, Radiation Epidemiology Branch, National Cancer Institute, Bethesda, MD, USA.
Robert J MacInnisCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
Giovanna MasalaClinical Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network (ISPRO), Florence, Italy.
Lene MellemkjærDanish Cancer Institute, Copenhagen, Denmark.
Roger L MilneCancer Epidemiology Division, Cancer Council Victoria, Melbourne, VIC, Australia.
David C MullerDepartment of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, UK.
Hannah Lui ParkDepartment of Pathology and Laboratory Medicine, Department of Epidemiology, UC Irvine School of Medicine, Irvine, CA, USA.
Kathryn J RuddyDepartment of Oncology, Mayo Clinic, Rochester, MN, USA.
Sven SandinDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Xiao-Ou ShuDepartment of Medicine, Institute for Medicine and Public Health, Division of Epidemiology, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Sandar Tin TinCancer Epidemiology Unit, Oxford Population Health, University of Oxford, Oxford, UK.
Thérèse TruongUniversité Paris-Saclay, UVSQ, Inserm, Gustave Roussy, CESP, 94805, Villejuif, France.
Celine M VachonDepartment of Quantitative Health Sciences, Division of Epidemiology, Mayo Clinic, Rochester, MN, USA.
Lars J VattenDepartment of Public Health and Nursing, Faculty of Medicine, Norwegian, University of Science and Technology, Trondheim, Norway.
Kala VisvanathanDepartment of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA.
Elisabete WeiderpassCancer, World Health Organization, International Agency for Research On , Lyon, France.
Walter WillettDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.
Alicja WolkInstitute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden.
Jian-Min YuanCancer Epidemiology and Prevention Program, UPMC Hillman Cancer Center, Pittsburgh, PA, USA.
Wei ZhengDepartment of Medicine, Institute for Medicine and Public Health, Division of Epidemiology, Vanderbilt Genetics Institute, Vanderbilt University Medical Center, Nashville, TN, USA.
Dale P SandlerEpidemiology Branch, National Institute of Environmental Health Sciences, Research Triangle Park, Durham, NC, USA.
Minouk J SchoemakerReal World Solutions, IQVIA, Amsterdam, Netherlands.
Anthony J SwerdlowDivision of Genetics and Epidemiology, The Institute of Cancer Research, London, UK.
A Heather EliassenDepartment of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA.

Funding

Long Term Multidisciplinary Study of Cancer in Women: The Nurses Health StudyUM1CA186107 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI ELIASSEN, A. HEATHER, STAMPFER, MEIR · 2014 to 2023
$22.3M
Training Program in Cancer EpidemiologyT32CA009001 · NCI · HARVARD UNIVERSITY (SCH OF PUBLIC HLTH) · PI A. Heather Eliassen, Meir Stampfer · 1985 to 2026
$17.3M
Life Course Cancer Epidemiology Cohort in WomenUM1CA176726 · NCI · HARVARD SCHOOL OF PUBLIC HEALTH · PI WILLETT, WALTER C. · 2013 to 2017
$15.7M
Prospective studies of cancer etiology and prevention in Shanghai and SingaporeR01CA144034 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2010 to 2014
$7.0M
THE SINGAPORE COHORT STUDY OF DIET AND CANCERR01CA080205 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI YUAN, JIAN-MIN · 1999 to 2009
$5.3M
Cancer epidemiology cohorts in Shanghai and Singapore UM1CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2014 to 2018
$4.3M
Genetic and Environmental Risk Factors for Breast Cancer: The Sister StudyZ01ES044005 · NIEHS · NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES · PI SANDLER, DALE P · 1999 to 2008
$1.3M
The Singapore Chinese Health StudyU01CA182876 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI YUAN, JIAN-MIN · 2019 to 2019
$150k
Intramural NIH HHS Z01 ES044005National Institutes of Health Division of Intramural Research NIEHS Z01-ES044005National Institutes of Health, United States UM1-CA176726National Institutes of Health, United States UM1-CA186107NCI NIH HHS R01 CA080205NCI NIH HHS R01 CA144034NCI NIH HHS T32 CA009001NCI NIH HHS U01 CA182876NCI NIH HHS UM1 CA176726NCI NIH HHS UM1 CA182876NCI NIH HHS UM1 CA186107NIH HHS R01-CA144034World Health Organization 001
6 · The paper itself

Abstract

backgroundIncidence of premenopausal breast cancer (BC) has risen in recent years, though most existing BC prediction models are not generalizable to young women due to underrepresentation of this age group in model development.

methodsUsing questionnaire-based data from 19 prospective studies harmonized within the Premenopausal Breast Cancer Collaborative Group (PBCCG), representing 783,830 women, we developed a premenopausal BC risk prediction model. The data were split into training (2/3) and validation (1/3) datasets with equal distribution of cohorts in each. In the training dataset variables were chosen from known and hypothesized risk factors: age, age at menarche, age at first birth, parity, breastfeeding, height, BMI, young adulthood BMI, recent weight change, alcohol consumption, first-degree family history of BC, and personal history of benign breast disease (BBD). Hazard ratios (HR) and 95% confidence intervals (CI) were estimated by Cox proportional hazards regression using age as time scale, stratified by cohort. Given that complete information on all risk factors was not available in all cohorts, coefficients were estimated separately in groups of cohorts with the same available covariate information, adjusted to account for the correlation between missing and non-missing variables and meta-analyzed. Absolute risk of BC (in situ or invasive) within 5 years, was determined using country-, age-, and birth cohort-specific incidence rates. Discrimination (area under the curve, AUC) and calibration (Expected/Observed, E/O) were evaluated in the validation dataset. We compared our model with a literature-based model for women < 50 years (iCARE-Lit).

resultsSelected model risk factors were age at menarche, parity, height, current and young adulthood BMI, family history of BC, and personal BBD history. Predicted absolute 5-year risk ranged from 0% to 5.7%. The model overestimated risk on average [E/O risk = 1.18 (1.14-1.23)], with underestimation of risk in lower absolute risk deciles and overestimation in upper absolute risk deciles [E/O 1st decile = 0.59 (0.58-0.60); E/O 10th decile = 1.48 (1.48-1.49)]. The AUC was 59.1% (58.1-60.1%). Performance was similar to the iCARE-Lit model.

conclusionIn this prediction model for premenopausal BC, the relative contribution of risk factors to absolute risk was similar to existing models for overall BC. The discriminatory ability was nearly identical (< 1% difference in AUC) to the existing iCARE-Lit model developed in women under 50 years. The inability to improve discrimination highlights the need to investigate additional predictors to better understand premenopausal BC risk.

Indexed as

Breast NeoplasmsPremenopauseAdultCohort StudiesFemaleHumansIncidenceMiddle AgedModels, StatisticalProportional Hazards ModelsProspective StudiesRisk AssessmentRisk FactorsPremenopausal breast cancerRisk prediction modelYoung-onset breast cancer

Identifiers

PMID40312753
PMCPMC12046669

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.